20-11-2024
FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim®
Read all
Fort Lee, NJ, USA, November 19, 2024 /PRNewswire/ – Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company’s manufacturing facility in Bolognana, Italy, to produce RYPLAZIM®. This plasma-derived human plasminogen is indicated for treating patients with plasminogen deficiency type 1 (PLGD-1), a rare and challenging chronic
02-10-2024
Kedrion and Biotest Finalize Yimmugo Commercialization for US
Read all
Following the agreement of binding terms signed in July 2024, Kedrion Biopharma Inc. and Biotest AG have now finalized the contractual terms of the long-term strategic agreement for the full commercialization and distribution of Biotest Immunoglobulin Yimmugo® in the United States. The exclusive distribution agreement requires Biotest to supply and Kedrion to purchase minimum quantities